One of the most promising opportunities within the biosciences for application of the TPR4000™ is for use in selective cancer therapies. Despite significant chemotherapeutic advances due to new drugs and combinatorial therapies over the past decades, cancer is still the second-leading cause of death in the United States.
Through a joint development agreement, breakthrough therapies are being developed by Symbios for Electrochemical Plasma Activated Aqueous Chemotherapeutics (EPAAC). In lab testing, plasma systems have demonstrated selective inhibitory effects on cancer cells, but until now there has been no commercially viable way to deliver the plasma species to internal tumors. The Symbios EPAAC is commercially scalable and represents an opportunity for a more cost-effective and safer chemotherapeutic approach.